Alembic Pharmaceuticals announces international business head resignation

Alembic Pharmaceuticals Limited has announced the resignation of prashant khandelwal, head – international business formulations, effective december 1, 2025, after the closure of business hours. The company formally communicated this change to both the bse limited and the national stock exchange of india ltd. on december 1, 2025. This move aligns with regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015.

Mr. khandelwal's resignation was tendered on september 1, 2025, with a notice period of three months. The company stated that all necessary details regarding this resignation have been provided in accordance with sebi's master circular no. sebi/ho/cfd/pod2/cir/p/0155 dated november 11, 2024. The announcement also clarified that there are no disclosures required regarding Mr. khandelwal's brief profile or relationships between directors, as these aspects are noted as "not applicable."

The departure of a senior executive from a critical business division like international business formulations could potentially impact the company's strategic operations in the global market. Alembic Pharmaceuticals Limited has confirmed compliance with all regulatory obligations by promptly informing the stock exchanges about this senior management change.